- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | Leerink Partners reiterates Outperform on Tenaya stock at $2 | 10 | Investing.com | ||
| 12.03. | William Blair reiterates Outperform on Tenaya Therapeutics stock | 15 | Investing.com | ||
| 11.03. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 192 | GlobeNewswire (Europe) | Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports... ► Artikel lesen | |
| TENAYA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.03. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy | 15 | GlobeNewswire (USA) | ||
| 06.03. | Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs | 11 | BioPharma Dive | ||
| 06.03. | Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal | 6 | Pharmaceutical Technology | ||
| 06.03. | Alnylam bets on Tenaya RNAi tech, and other licensing news | 4 | pharmaphorum | ||
| 05.03. | Tenaya Therapeutics Stock Jumps After New Alnylam Deal | 11 | Benzinga.com | ||
| 05.03. | Tenaya, Alnylam ink research collab to find gene targets for cardio drugs | 3 | FierceBiotech | ||
| 05.03. | Tenaya Enters Research Collaboration With Alnylam; To Receive Up To $10 Mln In Upfront Payments | 643 | AFX News | WASHINGTON (dpa-AFX) - Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY), to discover human genetic targets for the potential development... ► Artikel lesen | |
| 05.03. | Alnylam's research pact worth up to $1.1B sends Tenaya higher | 5 | Seeking Alpha | ||
| 05.03. | Tenaya, Alnylam partner on heart disease gene targets | 5 | Investing.com | ||
| 05.03. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.02. | Tenaya Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 8 | SEC Filings | ||
| 30.01. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.01. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones | 1.091 | GlobeNewswire (Europe) | Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK-1 Trial of Adults with MYBPC3-Associated HCM Expects to... ► Artikel lesen | |
| 02.01. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.25 | Tenaya Therapeutics: Canaccord senkt Kursziel auf 5 US-Dollar, bestätigt aber 'Buy'-Rating | 21 | Investing.com Deutsch | ||
| 18.12.25 | Tenaya Therapeutics stock price target lowered to $5 at Canaccord | 5 | Investing.com | ||
| 12.12.25 | Tenaya Stock Plunges After $60 Million Equity Offering | 8 | Benzinga.com |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| CRISPR THERAPEUTICS | 43,695 | 0,00 % | CRISPR Therapeutics-Aktie: Milliarden mit Gentherapie CASGEVY? | CRISPR Therapeutics vollzieht den Übergang von einem reinen Forschungsunternehmen zu einem kommerziellen Biotechnologieanbieter. Mit ersten nennenswerten Umsätzen und einer breiten Pipeline an innovativen... ► Artikel lesen | |
| OCUGEN | 1,524 | +1,74 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,917 | +0,94 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| BIONXT SOLUTIONS | 0,311 | -0,96 % | BioNxt sichert sich einheitliches europäisches Patent für seine sublinguale Cladribin-ODF-Plattform in 18 Ländern | VANCOUVER, BC / ACCESS Newswire / 7. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives Biowissenschaftsunternehmen, das
sich... ► Artikel lesen | |
| MAINZ BIOMED | 0,443 | -6,24 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,400 | -1,04 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| TEMPUS AI | 36,640 | +0,07 % | Trader-Interview mit Sascha Huber: Marvell Technology, Intuit, Salesforce, Tempus AI & MicroStrategy | In dieser Ausgabe des Trader-Interviews analysieren Andreas Bernstein und Sascha Huber die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit Fokus auf den Einfluss von Künstlicher Intelligenz... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,160 | +0,02 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen |
Das Unternehmen TENAYA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,045 (-6,05 %) liegt der Kurs bei 0,695 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TENAYA THERAPEUTICS INC finden Sie auf Wallstreet Online.